Good Evening,
A month ago, this story was about potential. Today, it is about the financial strength to reach the finish line. While others are waiting for clarity, this setup just hit a massive new gear.
Our last feature delivered an incredible 130% gain from its previous close to the high of the day,
and the latest move in this next one has our full attention. We don't circle back unless the landscape materially strengthens, and a fresh $33,000,000 capital injection has done exactly that.
The Mid-Phase Momentum:
- Registrational Execution: The pivotal Phase 3 study is officially active and enrolling.
- $33M Fully Funded: A massive capital raise was just completed,
led by sector-focused participants, to carry the program through completion.
- Active Regulatory Path: FDA Fast Track status is in place to support accelerated pathways.
The Clinical Validation: Recent data highlights survival results exceeding two years for multiple participants—nearly tripling the historical standard for this specific setting. Statistical modeling currently indicates
a 96% to 99% probability of technical success for the ongoing registrational studies.
Tomorrow at 9:30AM EST, we release the full breakdown of why this 33M refresh changes the entire timeline.
Be early.
Max Masters
Co-founder, Market Tips Newsletter
